tetano
Editor, Senior Moderator
Nippon Rinsho. 2010 Sep;68(9):1685-9.
[Present and future in a development of new anti-influenza drugs]
[Article in Japanese]
Watanabe A.
Research Division for Development of Anti-Infective Agents, Institute of Development, Aging and Cancer, Tohoku University.
Abstract
Against pandemic influenza A (H1N1) 2009, anti-influenza drugs were useful to save the disease aggravation and reduce the mortality. In addition to the existing anti-influenza drugs, novel drugs, including neuraminidase inhibitors (peramivir and laninamivir) and RNA polymerase inhibitors (favipiravir), also have clinical potentials to suppress pandemic influenza A (H1N1) 2009 virus as well as seasonal influenza virus.
PMID: 20845748 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/20845748
[Present and future in a development of new anti-influenza drugs]
[Article in Japanese]
Watanabe A.
Research Division for Development of Anti-Infective Agents, Institute of Development, Aging and Cancer, Tohoku University.
Abstract
Against pandemic influenza A (H1N1) 2009, anti-influenza drugs were useful to save the disease aggravation and reduce the mortality. In addition to the existing anti-influenza drugs, novel drugs, including neuraminidase inhibitors (peramivir and laninamivir) and RNA polymerase inhibitors (favipiravir), also have clinical potentials to suppress pandemic influenza A (H1N1) 2009 virus as well as seasonal influenza virus.
PMID: 20845748 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/20845748